NCT01523782View on ClinicalTrials.gov

Administration of GRASPA (Suspension of Erythrocytes Encapsulating L-asparaginase) in Elderly Patients With First Line Acute Lymphoblastic Leukemia

PHASE2CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

April 30, 2009

Primary Completion Date

January 31, 2011

Study Completion Date

October 31, 2012

Conditions
Acute Lymphoblastic Leukemia
Interventions
DRUG

GRASPA

Each patient will receive GRASPA at day 3 of the induction 1 phase. If no toxicity related to investigational product is observed and if the patient's state of health allows it, a second injection, at the identical dose, will be administered at Day 6 of Induction 2 phase

Sponsors

Lead Sponsor

ERYtech Pharma
All Listed Sponsors
lead

ERYtech Pharma

INDUSTRY